#JPM22: Highlights for the year ahead in oncology R&D — What’s hot, what’s not?

Across the broad spectrum of oncology drug development, 2021 marked a year of breakthroughs with off-the-shelf cell therapies coming into their own (with some questions) as classically “undruggable” targets fell to the inevitable march of progress.

In 2022, some of the brightest minds in oncology see the potential for even...

Click to view original post